Lantheus Holdings, Inc.
LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary functiā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$54.18
Price-0.53%
-$0.29
1Y
Price
Market Cap
$3.684b
Mid
Price/Earnings 3y Avg5y Avg
14.4x
Premium
Premium
Financials Overview
Key metrics over the past few years+26.1%
EBITDA Margin+15.8%
Net Profit Margin+18.7%
Free Cash Flow MarginRevenue
$1.521b
+10.9%
1y CAGR+56.5%
3y CAGR+48.7%
5y CAGREarnings
$271.003m
+31.2%
1y CAGR+411.5%
3y CAGR+201.3%
5y CAGREPS
$3.76
+31.2%
1y CAGR+410.5%
3y CAGR+226.9%
5y CAGRBook Value
$1.167b
$2.116b
Assets$949.294m
Liabilities$615.494m
DebtDebt to Assets
29.1%
1.1x
Debt to EBITDAFree Cash Flow
$473.192m
+52.6%
1y CAGR+193.8%
3y CAGR+386.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company